These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 32670541)
1. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Abdalla MA; Deshmukh H; Atkin S; Sathyapalan T Ther Adv Endocrinol Metab; 2020; 11():2042018820938305. PubMed ID: 32670541 [TBL] [Abstract][Full Text] [Related]
2. The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence. Abdalla MA; Deshmukh H; Atkin S; Sathyapalan T Ther Adv Endocrinol Metab; 2021; 12():2042018821989238. PubMed ID: 33552465 [TBL] [Abstract][Full Text] [Related]
3. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome. Tzotzas T; Karras SN; Katsiki N Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008 [TBL] [Abstract][Full Text] [Related]
5. New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome. Saleem F; Rizvi SW Cureus; 2017 Nov; 9(11):e1844. PubMed ID: 29344438 [TBL] [Abstract][Full Text] [Related]
6. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047 [TBL] [Abstract][Full Text] [Related]
7. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Svendsen PF; Nilas L; Madsbad S; Holst JJ Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579 [TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes. Ortiz-Flores AE; Luque-Ramírez M; Escobar-Morreale HF Expert Opin Pharmacother; 2018 Dec; 19(17):1915-1926. PubMed ID: 30289728 [TBL] [Abstract][Full Text] [Related]
10. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options. De Leo V; Musacchio MC; Palermo V; Di Sabatino A; Morgante G; Petraglia F Drugs Today (Barc); 2009 Oct; 45(10):763-75. PubMed ID: 20069140 [TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities. Elkind-Hirsch KE Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059 [TBL] [Abstract][Full Text] [Related]
12. Weight Management in Adolescents with Polycystic Ovary Syndrome. Moore JM; Waldrop SW; Cree-Green M Curr Obes Rep; 2021 Sep; 10(3):311-321. PubMed ID: 34043216 [TBL] [Abstract][Full Text] [Related]
13. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? Pugliese G; de Alteriis G; Muscogiuri G; Barrea L; Verde L; Zumbolo F; Colao A; Savastano S J Endocrinol Invest; 2023 Sep; 46(9):1761-1774. PubMed ID: 37093453 [TBL] [Abstract][Full Text] [Related]
14. Insulin and the polycystic ovary syndrome. Macut D; Bjekić-Macut J; Rahelić D; Doknić M Diabetes Res Clin Pract; 2017 Aug; 130():163-170. PubMed ID: 28646699 [TBL] [Abstract][Full Text] [Related]
16. Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. Marinkovic-Radosevic J; Cigrovski Berkovic M; Kruezi E; Bilic-Curcic I; Mrzljak A World J Diabetes; 2021 Jul; 12(7):932-938. PubMed ID: 34326946 [TBL] [Abstract][Full Text] [Related]
17. Why does Polycystic Ovary Syndrome (PCOS) Need Long-term Management? Ruan X; Li M; Mueck AO Curr Pharm Des; 2018; 24(39):4685-4692. PubMed ID: 30706800 [TBL] [Abstract][Full Text] [Related]
18. Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies. Szczesnowicz A; Szeliga A; Niwczyk O; Bala G; Meczekalski B J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762856 [TBL] [Abstract][Full Text] [Related]
19. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Naderpoor N; Shorakae S; de Courten B; Misso ML; Moran LJ; Teede HJ Hum Reprod Update; 2015; 21(5):560-74. PubMed ID: 26060208 [TBL] [Abstract][Full Text] [Related]
20. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Jeanes YM; Reeves S Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]